23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ALDEYRA THERAPEUTICS INC. › 2023-2024

ALDEYRA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ALDEYRA THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 127Asset managers, any item
  • 587Fund votes
  • June 4, 2024Meeting date

Results at a glance

Meeting of June 4, 2024: 4 items on ALDEYRA THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024: 2 elected · 2 approved.

Dissent

Significant dissent: 2 directors (36.5%, 34.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ALDEYRA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ALDEYRA THERAPEUTICS INC.

These tallies are ALDEYRA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ALDEYRA THERAPEUTICS INC. — official shareholder meeting results, meeting held June 4, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Nancy B. Miller-Rich 21,883,289---- 12,598,67610,177,898 63%Elected—
Elect Director: Ben R. Bronstein, M.D. 22,697,358---- 11,784,60710,177,898 66%Elected—
2. Ratification of Appointment of BDO USA, P.C 44,100,430372,785186,648 ---- 99.2%Approved—
3. Advisory Vote on Executive Compensation 31,493,3192,862,040126,606 --10,177,898 92%Approved—

Source: ALDEYRA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.

How asset managers voted at the ALDEYRA THERAPEUTICS INC. 2023-2024 meeting

127 asset managers disclosed a vote on at least one ALDEYRA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Ben R. Bronstein, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

66% Majority: yes · of votes cast

FOR 66%WITHHELD
FOR: 22,697,358WITHHELD: 11,784,607
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: Election of two Class I Directors: Ben R. Bronstein, M.D.

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ben R. Bronstein, M.D.”): 22,697,358 for, 11,784,607 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class I directors until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 2,907,026 for, 5,225,872 withheld, 352,503 abstained.

FORWITHHOLD
FOR: 2,907,026ABSTAIN: 352,503WITHHOLD: 5,225,872
Largest asset managers voting on “Election of two Class I Directors: Ben R. Bronstein, M.D.” at ALDEYRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard00 03,783,308Withhold
BlackRock1,740,6890 00For
Fidelity961,3750 00For
Dimensional00 0546,755Withhold
SEI00 0369,002Withhold
CARILLON SERIES TRUST00 283,5770Abstain
Equitable85,1870 056,690Mixed
Charles Schwab00 0125,525Withhold
TIAA00 098,308Withhold
QUANTITATIVE MASTER SERIES LLC78,1500 00For
Lincoln Financial00 048,794Withhold
Managed Portfolio Series00 27,9620Abstain
AIG/SunAmerica00 022,952Withhold
Jackson National00 21,1170Abstain
Nationwide5,4670 014,655Mixed
John Hancock00 18,9210Abstain
Northern Trust00 017,712Withhold
American Century00 017,136Withhold
State Street00 016,858Withhold
Voya00 016,086Withhold
Brighthouse00 015,823Withhold
Pacific Life14,8810 00For
Invesco00 011,271Withhold
Goldman Sachs10,8130 00For
T. Rowe Price00 010,567Withhold

Showing the 25 largest of 41 asset managers. All 41 are in the interactive database (link above).

Elect Director: Nancy B. Miller-Rich

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

63% Majority: yes · of votes cast

FOR 63%WITHHELD
FOR: 21,883,289WITHHELD: 12,598,676
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: Election of two Class I Directors: Nancy B. Miller-Rich

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Nancy B. Miller-Rich”): 21,883,289 for, 12,598,676 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class I directors until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 1,958,611 for, 6,174,287 withheld, 352,503 abstained.

FORWITHHOLD
FOR: 1,958,611ABSTAIN: 352,503WITHHOLD: 6,174,287
Largest asset managers voting on “Election of two Class I Directors: Nancy B. Miller-Rich” at ALDEYRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard00 03,783,308Withhold
BlackRock1,740,6890 00For
Fidelity00 0961,375Withhold
Dimensional00 0546,755Withhold
SEI00 0369,002Withhold
CARILLON SERIES TRUST00 283,5770Abstain
Equitable85,1870 056,690Mixed
Charles Schwab00 0125,525Withhold
TIAA00 098,308Withhold
QUANTITATIVE MASTER SERIES LLC78,1500 00For
Lincoln Financial00 048,794Withhold
Managed Portfolio Series00 27,9620Abstain
AIG/SunAmerica00 022,952Withhold
Jackson National00 21,1170Abstain
Nationwide00 020,122Withhold
John Hancock00 18,9210Abstain
Northern Trust17,7120 00For
American Century00 017,136Withhold
State Street00 016,858Withhold
Voya00 016,086Withhold
Brighthouse00 015,823Withhold
Pacific Life14,8810 00For
Invesco11,2710 00For
Goldman Sachs00 010,813Withhold
T. Rowe Price00 010,567Withhold

Showing the 25 largest of 41 asset managers. All 41 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

92% Approved · of votes cast

FOR 92%
FOR: 31,493,319AGAINST: 2,862,040

Prior year: 97.7% for (June 30, 2023 meeting) ▼ 6.0 pts

Details: description as filed, official tally, votes by 127 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S NAMED EXECUTIVE OFFICERS.

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 31,493,319 for, 2,862,040 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 40 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S NAMED EXECUTIVE” at ALDEYRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,783,3080 00For
BlackRock1,740,6890 00For
Fidelity961,3750 00For
Dimensional0546,755 00Against
SEI0369,002 00Against
CARILLON SERIES TRUST283,5770 00For
Equitable141,8770 00For
Charles Schwab125,5250 00For
TIAA98,3080 00For
QUANTITATIVE MASTER SERIES LLC78,1500 00For
Lincoln Financial38,30010,494 00Mixed
Managed Portfolio Series027,962 00Against
AIG/SunAmerica22,9520 00For
Jackson National021,117 00Against
Nationwide19,515607 00For
John Hancock18,9210 00For
Northern Trust17,7120 00For
American Century17,1360 00For
State Street16,8580 00For
Voya16,0860 00For
Brighthouse15,8230 00For
Pacific Life14,8810 00For
Invesco011,271 00Against
Goldman Sachs10,8130 00For
T. Rowe Price10,5670 00For

Fund voting reports, all 40 managers: 7,493,420 for, 991,981 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 102 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S NAMED EXECUTIVE” at ALDEYRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
PERCEPTIVE ADVISORS LLC9,221,4120 00For
BlackRock1,346,4200 00For
KENNEDY CAPITAL MANAGEMENT LLC1,232,0890 00For
GEODE CAPITAL MANAGEMENT, LLC1,028,2310 00For
EAGLE ASSET MANAGEMENT INC876,7050 00For
State Street850,1010 00For
SEI0370,081 00Against
Northern Trust343,90728 00For
PNC BANK, NATIONAL ASSOCIATION0301,505 00Against
MELLON INVESTMENTS Corp0225,990 00Against
Palo Alto Investors LP225,4650 00For
JACOBS LEVY EQUITY MANAGEMENT, INC178,9190 00For
ACADIAN ASSET MANAGEMENT LLC178,1700 00For
WOODSTOCK CORP0170,715 00Against
Charles Schwab125,5250 00For
Dimensional0101,664 00Against
Nuveen99,6870 00For
Vanguard91,8950 00For
STRS OHIO82,3000 00For
AllianceBernstein56,6900 00For
CIBC Private Wealth Group LLC51,4580 00For
JPMorgan50,5690 00For
T. Rowe Price48,2730 00For
DE Shaw47,5210 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC44,7080 00For

Institutional-manager reports, all 102 managers: 16,463,330 for, 1,411,839 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of BDO USA, P.C

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.2% Approved · of votes cast

FOR 99.2%
FOR: 44,100,430AGAINST: 372,785
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF BDO USA, P.C. AS ALDEYRA THERAPEUTICS, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2024.

ALDEYRA THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of BDO USA, P.C”): 44,100,430 for, 372,785 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of Appointment of BDO USA, P.C. The Company's stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 8,485,401 for.

FOR
FOR: 8,485,401
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF BDO USA, P.C. AS ALDEYRA THERAPEUTICS, INC.'S INDEPENDENT REGISTERED PUBLIC ACCOU” at ALDEYRA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard3,783,3080 00For
BlackRock1,740,6890 00For
Fidelity961,3750 00For
Dimensional546,7550 00For
SEI369,0020 00For
CARILLON SERIES TRUST283,5770 00For
Equitable141,8770 00For
Charles Schwab125,5250 00For
TIAA98,3080 00For
QUANTITATIVE MASTER SERIES LLC78,1500 00For
Lincoln Financial48,7940 00For
Managed Portfolio Series27,9620 00For
AIG/SunAmerica22,9520 00For
Jackson National21,1170 00For
Nationwide20,1220 00For
John Hancock18,9210 00For
Northern Trust17,7120 00For
American Century17,1360 00For
State Street16,8580 00For
Voya16,0860 00For
Brighthouse15,8230 00For
Pacific Life14,8810 00For
Invesco11,2710 00For
Goldman Sachs10,8130 00For
T. Rowe Price10,5670 00For

Showing the 25 largest of 41 asset managers. All 41 are in the interactive database (link above).

Largest ALDEYRA THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 59,414,489 shares outstanding at the time of that meeting.

Fund voting reports: top ALDEYRA THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 6.37%
2BlackRock 2.93%
3Fidelity 1.62%
4Dimensional 0.92%
5SEI 0.62%
6CARILLON SERIES TRUST 0.48%
7Equitable 0.24%
8Charles Schwab 0.21%
9TIAA 0.17%
10QUANTITATIVE MASTER SERIES LLC 0.13%
Institutional-manager reports: top ALDEYRA THERAPEUTICS INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S…”, 2023-2024
#Asset manager % of shares outstanding
1PERCEPTIVE ADVISORS LLC 15.52%
2BlackRock 2.27%
3KENNEDY CAPITAL MANAGEMENT LLC 2.07%
4GEODE CAPITAL MANAGEMENT, LLC 1.73%
5EAGLE ASSET MANAGEMENT INC 1.48%
6State Street 1.43%
7SEI 0.62%
8Northern Trust 0.58%
9PNC BANK, NATIONAL ASSOCIATION 0.51%
10MELLON INVESTMENTS Corp 0.38%

Reported ALDEYRA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ALDEYRA THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Perceptive Advisors LLC8,593,586 14.46%Proxy statement (DEF 14A), proxy filed April 22, 2024
BlackRock3,804,920 6.40%Form 13F, quarter ended March 31, 2024
Knoll Capital Management, LLC3,595,916 6.05%Proxy statement (DEF 14A), proxy filed April 22, 2024
Vanguard Group3,591,869 6.05%Form 13F, quarter ended March 31, 2024
Todd C. Brady, M.D., Ph.D.3,028,391 5.10%Proxy statement (DEF 14A), proxy filed April 22, 2024
Morgan Stanley1,083,319 1.82%Form 13F, quarter ended March 31, 2024
State Street939,569 1.58%Form 13F, quarter ended March 31, 2024
Dimensional Fund Advisors882,210 1.48%Form 13F, quarter ended March 31, 2024
Renaissance Technologies727,690 1.22%Form 13F, quarter ended March 31, 2024
Stephen G. Machatha, Ph.D.716,162 1.21%Proxy statement (DEF 14A), proxy filed April 22, 2024

Percentages above are of 59,414,489 shares outstanding, as reported by ALDEYRA THERAPEUTICS INC. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ALDEYRA THERAPEUTICS INC.'s shareholder meeting held June 4, 2024, in the 2023-2024 proxy season, 127 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 587 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF ALDEYRA THERAPEUTICS, INC.'S… — ALDEYRA THERAPEUTICS INC.'s filing reports the proposal as approved, with 92% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALDEYRA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALDEYRA THERAPEUTICS INC.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ALDEYRA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ALDEYRA THERAPEUTICS (ALDX) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/aldeyra-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.